Zealand Pharma
301.90 DKK
+1.82 %
Less than 1K followers
ZEAL
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Zealand Pharma
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 41.3 | 353.3 | 292.6 | 104.0 | 342.8 | 62.7 | 9,214.9 |
| growth-% | 754.8 % | -17.2 % | -64.5 % | 229.6 % | -81.7 % | 14,599.1 % | |
| EBITDA | -587.9 | -749.7 | -1,012.1 | -837.2 | -572.2 | -1,272.2 | 6,986.8 |
| EBIT | -587.9 | -792.4 | -1,052.4 | -837.2 | -572.2 | -1,272.2 | 6,959.4 |
| Profit before taxes | -576.7 | -839.7 | -1,026.9 | -972.0 | -708.9 | -1,083.5 | 7,001.1 |
| Net income | -571.5 | -846.7 | -1,018.1 | -1,202.1 | -703.7 | -1,078.8 | 6,455.0 |
| EPS | -16.91 | -21.28 | -23.75 | -26.02 | -12.44 | -16.24 | 91.56 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | 0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -1,422.5 % | -212.2 % | -345.9 % | -805.0 % | -166.9 % | -2,029.4 % | 75.8 % |
| EBIT-% | -1,422.5 % | -224.3 % | -359.7 % | -805.0 % | -166.9 % | -2,029.4 % | 75.5 % |
| ROE | -46.0 % | -68.9 % | -109.7 % | -147.3 % | -44.2 % | -12.5 % | 43.5 % |
| ROI | -35.7 % | -48.1 % | -49.2 % | -78.1 % | -35.5 % | -11.3 % | 40.5 % |